Study on ICG for Enhanced Visualization of Ureters in Deep Infiltrating Endometriosis
The ongoing clinical trial on ICG for ureter visualization in endometriosis surgery could significantly alter surgical practices and improve patient outcomes. If successful, it may reduce reliance on high-risk ureterolysis procedures, positioning the sponsoring institutions as leaders in innovative surgical techniques.
Phase III
Gynecology / Endometriosis
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The ongoing clinical trial on ICG for ureter visualization in endometriosis surgery could significantly alter surgical practices and improve patient outcomes. If successful, it may reduce reliance on high-risk ureterolysis procedures, positioning the sponsoring institutions as leaders in innovative surgical techniques.
Why it matters
The ongoing clinical trial on ICG for ureter visualization in endometriosis surgery could significantly alter surgical practices and improve patient outcomes. If successful, it may reduce reliance on high-risk ureterolysis procedures, positioning the sponsoring institutions as leaders in innovative surgical techniques.
What changed
Trial Update
Analysis
A clinical trial is investigating the use of ICG for improved visualization of ureters during laparoscopic surgery in patients with deep infiltrating endometriosis.
The ongoing clinical trial on ICG for ureter visualization in endometriosis surgery could significantly alter surgical practices and improve patient outcomes. If successful, it may reduce reliance on high-risk ureterolysis procedures, positioning the sponsoring institutions as leaders in innovative surgical techniques.
Monitor the trial's progress, particularly the feasibility results and safety data regarding ICG use in this context.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.